Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
New findings from Y. Zhang and co-authors describe advances in cancer gene therapy
January 27th, 2009
According to recent research from Guangzhou, People's Republic of China, " The failure of hormone treatment for advanced prostate cancer might be related to aberrant activation of the androgen receptor. We have shown that I-125 labeled triple-helix forming oligonucleotide (TFO) against the androgen receptor gene inhibits androgen receptor expression and cell proliferation of LNCaP prostate cancer cells in vitro." "This study aimed at exploring the effects of the I-125-TFO on prostate tumor growth in vivo using a nude mouse xenograft model. TFO was labeled with I-125 by the iodogen method. Thirty-two nude mice bearing LNCaP xenograft tumors were randomized into 4 groups...
Source: Cancer Weekly (2009-01-27)
|
